Study to Determine the Potential of TG-C for Damage Reduction in Subjects With Osteoarthritis (OA) of the Knee

Clinical Trial Title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee - ACTiVION II study

National Clinical Trial Number:

NCT03291470

Contact Information

Joshlean Fair

Call (312) 563-2955

Send Email

Clinical Trial Protocol Description:

An investigational new drug, TC-G, will be studied for the effects on people with osteoarthritis (OA) of the knee.
This study will find out if the drug, TC-G, can reduce damage caused by osteoarthritis, as well as collect more information about joint structure and knee symptoms as a result of OA. Over a period of 24 months, this study will require several appointments consisting of survey questionnaires, physical assessments, and imaging of the knee (X-ray and MRI).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

Are 40 years of age or older.
Have a BMI under 40.
Are able to have X-ray and MRI images taken of the knee.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.